Naobios News and Resources

Naobios has reached a critical milestone in the production of an HIV-1 vaccine candidate for Korean-Canadian biotechnology firm Sumagen Canada Inc. The achievement marks the completion of bench-scale production of Sumagen’s SAV001 vaccine, a genetically modified, whole-killed HIV vaccine designed